1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
SpectraCure AB (publ)

SpectraCure AB (publ)

SPEC.ST
SpectraCure AB (publ)SE flagStockholm Stock Exchange
0.06
SEK
+0.00
- -
24.46MMarket Cap
SpectraCure AB (publ)
SPEC.ST
(Stockholm Stock Exchange)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.05
-0.07
-0.09
-0.06
-0.05
-0.07
-0.07
-0.1
-0.11
-0.09
-0.17
-0.2
-0.14
Basic EPS, GAAP
-0.01
-0.12
-0.33
0.02
-0.1
-0.13
-0.09
-0.12
-0.14
-0.15
-0.26
-0.15
-0.11
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.22
-0.27
-0.38
-0.29
-0.17
-0.44
-0.51
-0.36
-0.47
-0.56
-1.09
-0.62
-0.42
Book Value per Share
-0.09
0.09
0.19
0.01
0.24
0.27
0.7
0.53
0.38
0.23
0.1
0.03
0.03
Tangible Book Value per Share
85
85
71
134
184
194
217
228
228
228
138
283
395
Basic Weighted Avg Shares
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-851.79
-738.73
-3,941.99
-3,358.37
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
1
- -
- -
1
- -
2
2
3
3
3
3
30
30
Depreciation Expense
-4
-6
-6
-9
-10
-14
-15
-23
-25
-20
-23
-56
-56
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-912.64
-755.89
-3,685.2
-3,358.38
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-4
8
13
2
43
49
149
118
82
48
11
6
8
Working Capital
- -
- -
- -
- -
- -
5
3
2
- -
4
3
- -
- -
LT Debt
-3
13
22
13
65
88
197
176
150
130
107
94
100
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3
3
2
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
410
410
410
Market Capitalization
52
43
35

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
29
16
19
Cash, Cash Equivalents & STI
26
14
17
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
- -
Total Current Liabilities
9
11
11
Payables & Accruals
- -
- -
- -
ST Debt
3
3
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
50.48%
-13.83%
-12.45%
Free Cash Flow
-86.51%
17.49%
19.97%
Net Income, GAAP
30.73%
39.42%
143.78%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
-0.03
-0.05
-0.01
-0.17
2025
-0.15
-0.03
-0.09
-0.02
-0.2
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Electromed, Inc. (ELMD)
Lifeward Ltd. (LFWD)
VentriPoint Diagnostics Ltd. (VPT.V)
Enchanted World Inc. (ENCW)
BBS-Bioactive Bone Substitutes Oyj (BONEH.HE)
Novacyt S.A. (NVYTF)
Business
SpectraCure AB (publ) specializes in advanced medical technology for cancer treatment, developing a proprietary system that combines laser light sources with photoreactive drugs through interstitial photodynamic therapy (PDT). Central to their approach is the patented IDOSE® software, designed to precisely control laser light dosage for optimal tumor elimination. The company is actively conducting a Phase II clinical study in North America and Europe for recurrent localized prostate cancer, and has initiated a Phase I/II study for primary localized prostate cancer. This innovative system aims to offer a highly precise, individualized, and minimally invasive solution for solid tumors, with future potential for applications in breast, pancreatic, and head and neck cancers. SpectraCure was established in 2003 as a spin-off from Lund University and operates from Lund, Sweden.